Aradigm's liquid asset

Genentech Inc. likely could have had its choice of partners to augment the delivery of its Pulmozyme dornase alfa Inhalation Solution to treat cystic fibrosis. The company chose Aradigm Corp. for two primary reasons: the potential to cut down on the time patients spend receiving treatment and the feasibility of delivering Pulmozyme with ARDM's AERx liquid delivery system as opposed to